ERBB2 and neoplasm: Early results of the combined treatment of tebotelimab and margetuximab in advanced HER2+ tumors, including BC, bile duct cancer, esophageal adenocarcinoma, microsatellite-stable colon cancer, and GEJ cancer, have shown encouraging anti-tumor activity (ORR, 19%) and acceptable safety (grade ≥ 3 TRAEs, 16.7%).